NCCN 2021 Virtual Oncology Fellows Program: New Horizons in Quality Cancer Care

March 17, 2021

The NCCN 2021 Virtual Oncology Fellows Program is a half-day informative and interactive program with clinical program content focusing on issues and tumor types that medical oncology fellows, surgical fellows, and radiation oncology residents confront on a daily basis. The program will provide an opportunity for early career physicians to understand the thought processes of experienced experts as they manage patient care and allow them to discuss the application of their training with some of the leading experts in the United States in a relatively small and informal setting. 

The goal of this program is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other evidence-based treatment principles in the management of significant cancer types, and supportive care and professional development issues. In addition, it's to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

Target Audience

This educational program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
•   Evaluate advances in the management of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care. 
•   Review issues related to telemedicine and cancer care: lessons for the future; optimal management of VTE in cancer patients; survivorship: from AYA to older adults; multidisciplinary management of early-stage lung cancer; and, multidisciplinary treatment of prostate cancer; and the importance of mentorship.

Telemedicine and Cancer Care: Lessons for the Future
•   Review the benefits of telemedicine for cancer care
•   Identify the unique challenges and limitations that can arise with telemedicine
•   Determine which patient encounters are appropriate for telemedicine

Optimal Management of Venous Thromboembolism in Patients with Cancer
•   Describe clinical situations where therapeutic anticoagulation would be an appropriate option for treatment of cancer-associated venous thromboembolism (VTE)
•   List factors to consider (including contraindications) when selecting among the recommended options for therapeutic VTE anticoagulation in patients with cancer
•   Describe consideration for management of patients with cancer-associate VTE in the event of therapeutic anticoagulation failure

Survivorship: From Adolescents and Young Adults to Older Adults
•   List common physical, psychological, and psychosocial late and long-term effects associated with cancer and its treatment
•   Discuss special considerations for survivorship care in AYA and older adult populations
•   Develop strategies for screening and management of late and long-term effects and for encouraging wellness in cancer survivors of all ages

Multidisciplinary Treatment of Early-Stage Non-Small Cell Lung Cancer
•   Discuss the need for multidisciplinary evaluation before treatment for patients with early-stage non-small cell lung cancer (NSCLC)
•   Describe multidisciplinary treatment for patients with medically operable early-stage NSCLC
•   Describe multidisciplinary treatment for patients with medically inoperable early-stage NSCLC

Multidisciplinary Treatment of Prostate Cancer
•   Provide an overview of the treatments used to treat patients with prostate cancer
•   Discuss the roles that genetics and diagnostic radiology professionals play in the optimal management of prostate cancer
•   Understand management strategies for supportive care issues in patients with prostate cancer

The Importance of Mentorship
•   Explain the benefits of the mentor-mentee relationship and learn how to get the most out of this relationship
•   Recognize the qualities and attributes of an appropriate mentor and how to identify the right match 
•   Describe the difference between a mentor, a sponsor, and a coach

Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Pfizer Inc.

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This educational activity is supported by an independent educational grant from Merck  & Co., Inc.

Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Participation
Course opens: 
03/16/2021
Course expires: 
06/06/2021
Event starts: 
03/17/2021 - 12:30pm EDT
Event ends: 
03/17/2021 - 6:00pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care.  Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. 

Definitions  

NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships: 

Anthony V. D'Amico, MD, PhD
Stéphanie Gaillard, MD, PhD
Sandra S. Hatch, MD
Christine E. Hill-Kayser, MD
Elaine Walsh, MB BCh, PhD

The faculty listed below discloses the following relevant financial relationships: 

Thomas J. Dilling, MD, MS
AstraZeneca Pharmaceuticals LP: Consulting Fee; Honoraria

Tanya Dorff, MD
AbbVie, Inc.: Consulting Fee
Bayer HealthCare: Consulting Fee
Exelixis Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee

Stéphanie Gaillard, MD, PhD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Elevar Therapeutics: Consulting Fee

Michael Lanuti, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee

Gregory A. Otterson, MD
AbbVie, Inc.: Grant/Research Support 
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Consulting Fee
Bristol-Myers Squibb Company: Grant/Research Support; Consulting Fee
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novocure: Consulting Fee
Pfizer Inc.: Grant/Research Support
Revolution Medicine: Grant/Research Support

Edward Schaeffer, MD, PhD 
Janssen Scientific Affairs, LLC: Scientific Advisor
Pfizer Inc.: Scientific Advisor

Michael B. Streiff, MD
Bayer HealthCare: Honoraria
Bristol-Myers Squibb Company: Scientific Advisor; Consulting Fee
Dispersol Technologies: Consulting Fee
Janssen Pharmaceutica Products, LP: Scientific Advisor; Consulting Fee
Novo Nordisk A/S: Grant/Research Support
Pfizer Inc.: Consulting Fee; Honoraria
sanofi-aventis U.S.: Grant/Research Support

NCCN Staff Disclosures

The NCCN Leadership listed below discloses no relevant financial relationships: 

Wui-Jin Koh, MD

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships: 

Deborah A. Freedman-Cass, PhD; Anita M. Engh, PhD; Liz Hollinger, RN, BSN; Miranda Hughes, PhD; Nicole R. McMillian, MS, CHES; Dorothy A. Shead, MS

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Please log in with the same email address used for program registration.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing